Investigating how a gene affects fat metabolism in brain tumors in children
Neurofibromin 1 as a novel regulator of lipid metabolism
This study is looking at how a gene called Nf1 affects fat processing in serious brain tumors in kids, with the hope of finding new ways to treat these tumors and help improve the health of children facing this challenge.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11075431 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Neurofibromin 1 (Nf1) in lipid metabolism and its connection to pediatric high-grade gliomas, which are serious brain tumors in children. The study aims to explore how the loss of Nf1 affects fat metabolism in these tumors and whether targeting this metabolic change could lead to new treatment options. By analyzing genetic and protein data from tumor samples, the research seeks to uncover potential therapeutic strategies that could improve outcomes for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years who have been diagnosed with high-grade gliomas or have a genetic predisposition to brain tumors due to Neurofibromatosis Type I.
Not a fit: Patients with brain tumors unrelated to Neurofibromatosis Type I or those outside the pediatric age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment approaches for pediatric brain tumors, potentially improving survival rates and quality of life for young patients.
How similar studies have performed: While the specific approach of targeting lipid metabolism in pediatric high-grade gliomas is novel, there is ongoing research into metabolic interventions in cancer treatment that has shown promise.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Gatesman, Taylor — University of Pittsburgh at Pittsburgh
- Study coordinator: Gatesman, Taylor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.